Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 177Lu-DOTA-cG250 in advanced renal cancer
2008-004548-35Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of girentuximab in clear cell renal cell carcinoma (ccRCC), sponsored by Radboud University Medical Center. Primary endpoints: Clinical efficacy by RECIST after up to three treatment cycles and Treatment toxicity by CTCAE v3.0. Started Nov 2009; status: completed.
02
Drugs
girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2008-004548-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004548-35.